Intravenous Iron Repletion in Patients With Continuous-Flow Left Ventricular Assist Devices.
Intravenous Iron Repletion in Patients With Continuous-Flow Left Ventricular Assist Devices.
复制标题
使用连续流左心室辅助装置的患者的静脉补铁。
DOI：
10.1097/mat.0000000000001800
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Mehra,MandeepR
中科院分区：
文献类型：
--
作者：
Bernier,ThomasD;Stern,Gretchen;Buckley,LeoF;Vieira,JeffersonL;Siddiqi,HasanK;Mehra,MandeepR
方法本研究经马萨诸塞州布里格姆机构审查委员会批准。在2015年1月至2019年8月期间接受CF-LVAD植入术并接受至少一剂IV铁剂的患者，如果他们在IV铁剂治疗前和治疗后90天内测量了可用血红蛋白（Hgb）、平均红细胞体积（MCV）、铁蛋白或转铁蛋白饱和度（TSAT），则纳入研究。如果患者在初始IV铁剂给药后90天内接受输血或在CF-LVAD植入后30天内开始IV铁剂给药，则将其排除。如果HFrEF患者的左心室射血分数≤ 30%，估计肾小球滤过率> 45 ml/min/1.73 m2，不需要CF-LVAD支持，并且在同一时间段内接受了IV铁剂治疗，未给予血液制品，则选择HFrEF患者的对照队列。
MethodsThis study was approved by the Mass General Brigham Institutional Review Board. Patients who underwent CF-LVAD implantation and received at least one dose of IV iron between January 2015 and August 2019 were included if they had available hemoglobin (Hgb), mean corpuscular volume (MCV), ferritin, or transferrin saturation (TSAT), measurements before and up to 90 days after IV iron treatment. Patients were excluded if they received a blood transfusion during the 90 days after initial IV iron administration or IV iron administration began within 30 days of CF-LVAD implant. A control cohort of HFrEF patients was selected if they had a left ventricular ejection fraction≤ 30% with an estimated glomerular filtration rate of> 45 ml/min per 1.73 m 2, did not require CF-LVAD support, and had received IV iron therapy with no blood products administration during the same time period.